Lumexa Imaging Holdings Inc. (LMRI) 12-Month Stock Forecast & Price Target Cone

LMRI scores 54 out of 100, a D+ grade with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

• Fundamental Cash Engine: 11 / 20. ROIC is 0% and FCF yield is 0%.
• Whale 13F Flow: 11 / 20. this pillar reflects institutional accumulation and options positioning. The holder section is empty in the source data, so the pillar cannot be traced to specific filings here.
• Insider Conviction: 9 / 20. this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, and the source data contains no insider transaction detail to explain it.
• Macro Regime Fit: 10 / 20. beta is 1.0 and sector sensitivity is weighted here. This is a market-average sensitivity profile with no stated macro edge.
• Forensic Balance Sheet: 13 / 20. Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 1.4. This is the strongest pillar, but it is still moderate.

For a prospective investor, the rating points to weak current earnings power and reliance on balance-sheet strength rather than cash generation. The source data shows zero reported revenue and zero operating income for FY 2025, so the valuation case rests on factors outside the reported financials. Investors weighing the stock should treat the 54 score as a signal that fundamentals do not currently support the price on the data provided. This is educational analysis, not personalized financial advice.

And profile, Lumexa Imaging Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical Specialities industry. The source data identifies the company's products, customers, and revenue model only at the sector level.

The FY 2025 period reports zero revenue, zero operating income, and zero net income, with cash of $58.8M against debt of $819.0M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity at 1.4. The debt load is large relative to the cash position shown, so the balance sheet relies on the scores above rather than on demonstrated profitability.

• 🐂 Primary Bull Case: Recent coverage and a headline on possible profitability within a year, with a Forensic Balance Sheet pillar score of 13 / 20 supporting solvency. With Fundamental Cash Engine at 11/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 10/20, sustained execution supports upside toward the top of the $6.45 – $19.45 52-week range.
• 🐻 Primary Bear Case: Zero reported FY 2025 revenue and operating income against $819.0M of debt, with ROIC and FCF yield both at 0%. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

The source data therefore does not map upstream suppliers, downstream customers, or sector co-dependencies for LMRI. Sector and industry classification (Health Care, Medical Specialities) is the only context available. Second-order bottlenecks cannot be identified from the provided data. Investors should note that the absence of mapped links is a data gap, not evidence that no dependencies exist.

• Key Question #1: What is the company's actual revenue base, given that FY 2025 revenue is reported at —?
• Key Question #2: What drives the $819.0M debt position, and what are its maturity schedule and interest costs?
• Key Question #3: What is the basis for the "less than a year away from profitability" headline, and what timeline does it assume?